Sedative and cardiovascular effects of intranasal or intramuscular dexmedetomidine in healthy dogs

Autor: Giancarlo Vesce, Fabiana Reynaud, Bruna Santangelo, Giovanni Della Valle, Giusy Napoleone, Karine Portier, Alessandro Mirra, Fabiana Micieli
Přispěvatelé: Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Micieli, Fabiana, Santangelo, Bruna, Reynaud, Fabiana, Mirra, Alessandro, Napoleone, Giusy, DELLA VALLE, Giovanni, Portier, Karine G, Vesce, Giovanni
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Bradycardia
medicine.medical_specialty
040301 veterinary sciences
medicine.drug_class
Sedation
[SDV]Life Sciences [q-bio]
Conscious Sedation
Cardiovascular System
Injections
Intramuscular
0403 veterinary science
03 medical and health sciences
Dogs
0302 clinical medicine
030202 anesthesiology
Heart rate
medicine
Animals
Hypnotics and Sedatives
Dexmedetomidine
Administration
Intranasal
ComputingMilieux_MISCELLANEOUS
2. Zero hunger
intramuscular
[SDV.BA.MVSA]Life Sciences [q-bio]/Animal biology/Veterinary medicine and animal Health
General Veterinary
Dexmedetomidine
dog
intranasal
intramuscular
sedation
business.industry
intranasal
dexmedetomidine
04 agricultural and veterinary sciences
3. Good health
Surgery
Blood pressure
sedation
Anesthesia
Sedative
dog
Mann–Whitney U test
Onset of action
medicine.symptom
business
medicine.drug
Zdroj: Veterinary Anaesthesia and Analgesia
Veterinary Anaesthesia and Analgesia, Wiley, 2017, 44 (4), pp.703--709. ⟨10.1016/j.vaa.2016.08.009⟩
Veterinary Anaesthesia and Analgesia, Wiley, 2017, 44 (4), pp.703-709. ⟨10.1016/j.vaa.2016.08.009⟩
ISSN: 1467-2987
1467-2995
DOI: 10.1016/j.vaa.2016.08.009⟩
Popis: International audience; OBJECTIVE: To compare the clinical effects and sedation scores following either intranasal (IN) or intramuscular (IM) administration of dexmedetomidine in dogs. STUDY DESIGN: Prospective, blinded, randomized, clinical study. ANIMALS: A total of 20 client-owned dogs scheduled for noninvasive diagnostic procedures. METHODS: Dogs were allocated to be administered dexmedetomidine 0.02 mg kg(-1) IN (IN group) or IM (IM group). Sedation was scored before and at 5 minute intervals (for 45 minutes) after drug administration using a composite simple descriptive sedation scale giving a score of 0 (not sedated) to 13 (well sedated). Respiratory frequency (fR), heart rate, haemoglobin oxygen saturation (SpO2) and noninvasive arterial blood pressure were recorded every 5 minutes for 45 minutes. Normally distributed data were analyzed using two-way ANOVA and post hoc Sidak's multiple comparison test. Non-normally distributed data were compared using the Scheier Ray Hare test and post hoc Mann-Whitney U test. Statistical significance was set at p\textless0.05. RESULTS: Weight, age and sex were not different between groups. Dexmedetomidine onset of action after IN administration was not shorter compared to IM administration (6.3+/-3.3 versus 9.4+/-4.6 minutes, p=0.120). Sedation score in the IN group was higher [10 (0-11)] compared to the IM group [6 (0-8)] (p\textless0.001). At time of peak sedation, heart rate decreased 56% from baseline values in the IM group, and 18% in the IN group. No significant differences in SpO2 and fR were found between the two groups at any time point. No undesirable effects were observed. CONCLUSIONS AND CLINICAL RELEVANCE: Intranasal dexmedetomidine 0.02 mg kg(-1) produced effective sedation with less bradycardia and more profound sedation compared to IM administration in healthy dogs and may be considered as an alternative route for dexmedetomidine administration in dogs.
Databáze: OpenAIRE
Externí odkaz: